Hansoh Pharma’s Cancer Drug Fast-Tracked by FDA

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.

Hansoh Pharmaceutical’s partner, GlaxoSmithKline, has received FDA Breakthrough Therapy Designation for HS-20093, a novel lung cancer treatment, highlighting promising trial results. This endorsement will expedite the development of HS-20093, which is showing potential against small-cell lung cancer after initial chemotherapy failure. The full data will be unveiled at the upcoming World Conference on Lung Cancer in 2024.

For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.